Literature DB >> 7652690

Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy.

A L Khan1, S Richardson, J Drew, F Larsen, M Campbell, S D Heys, A K Ah-See, O Eremin.   

Abstract

BACKGROUND: Surgical procedures suppress host antitumor defense mechanisms, which may increase the risk of metastatic tumor dissemination. We have evaluated the effects of the biologic response modifier polyadenylic-polyuridylic acid (PAPU) on natural cytotoxicity in patients with breast cancer undergoing operation.
METHODS: PAPU (150 mg) or placebo was given intravenously during the perioperative period (preoperative, days -1 and 0; postoperative, days 1, 3, 5, 7, and 14). The function (chromium release assay) and number (flow cytometry) of natural killer (NK) cells were measured before operation (days -2 and -1), on the day of operation (day 0), and after operation (days 1, 2, 4, 6, and 18).
RESULTS: Surgical procedures suppressed NK cell cytotoxicity in the placebo group on postoperative days 1 (p < 0.001), 4, 6, and 18 (p < 0.05), whereas inhibition on postoperative day 2 failed to reach significance. PAPU abolished this immunosuppression after operation. The NK cell activity was elevated when compared with the control group; it was significant (p < 0.05) on postoperative days 1, 2, 4, 6, and 18. Surgical procedures also reduced circulating NK cell numbers during the first postoperative week in the placebo group; the decrease was statistically significant on day 4. The decrease in NK cell numbers in the PAPU group was insignificant.
CONCLUSIONS: PAPU prevented the decrease in the circulating number and cytotoxic activity of NK cells that occurred after operation and enhanced NK cell cytotoxicity. This may have important implications for patients with cancer undergoing major operation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7652690     DOI: 10.1016/s0039-6060(05)80370-8

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

2.  Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.

Authors:  Takashi Akazawa; Takashi Ebihara; Manabu Okuno; Yu Okuda; Masashi Shingai; Kunio Tsujimura; Toshitada Takahashi; Masahito Ikawa; Masaru Okabe; Norimitsu Inoue; Miki Okamoto-Tanaka; Hiroyoshi Ishizaki; Jun Miyoshi; Misako Matsumoto; Tsukasa Seya
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

3.  Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials.

Authors:  S D Heys; L G Walker; I Smith; O Eremin
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

4.  Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis.

Authors:  Salomé González-Reyes; Laura Marín; Lucía González; Luis O González; José M del Casar; Maria L Lamelas; José M González-Quintana; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2010-12-03       Impact factor: 4.430

5.  Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery.

Authors:  Chandan Verma; Viriya Kaewkangsadan; Jennifer M Eremin; Gerard P Cowley; Mohammad Ilyas; Mohamed A El-Sheemy; Oleg Eremin
Journal:  J Transl Med       Date:  2015-06-04       Impact factor: 5.531

6.  Biological role of NK cells and immunotherapeutic approaches in breast cancer.

Authors:  María P Roberti; José Mordoh; Estrella M Levy
Journal:  Front Immunol       Date:  2012-12-12       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.